Axo-glial dysjunction refers to the disruption of important junctional complexes that anchor terminal loops of myelin to the paranodal axolemma in diabetic human and animal peripheral nerve. Neither axo-glial dysjunction nor the preceeding acute localized paranodal swelling has been specifically attributed to discrete metabolic consequences of insulin deficiency or hyperglycemia. Two metabolic sequelae of hyperglycemia in diabetic nerve, sorbitol accumulation via aldose reductase, and (NaK)-ATPase deficiency related to myo-inositol depletion, were explored as possible underlying causes of acute paranodal swelling in the spontaneously diabetic bio-breeding rat. 3 wk of insulin replacement, or therapy with an aldose reductase inhibitor or myo-inositol completely reversed paranodal swelling in sural nerve fibers after 3 wk of untreated insulin deficiency. These observations suggest that insulin deficiency and hyperglycemia cause reversible paranodal swelling, and ultimately poorly reversible axo-glial dysfunction, via the myo-inositol-related (Na,K)-ATPase defect rather than by the osmotic effects of sorbitol accumulation within nerve fibers.
Introduction
In the last decade, a cascade of metabolic abnormalities in diabetic peripheral nerve, triggered by hyperglycemia and involving myo-inositol (MI)' and (Na,K)-ATPase, has to a large extent satisfactorily explained the rapidly reversible slowing of nerve conduction in acutely diabetic rodents (1, 2) ; yet, the relationship of this metabolic cascade to the chronic and more pathogenetically relevant structural abnormalities characterizing both murine and human diabetic neuropathy remains to be clarified (2, 3) . Activation of the polyol pathway by hyperglycemia appears to be an essential triggering event, since aldose reductase inhibitors (ARI) prevent MI depletion (4) (5) (6) , the associated (Na,K)-ATPase defect (7) , and the resultant reversible slowing of nerve conduction in diabetic animals (6) ; competitive inhibition by glucose of carrier-mediated MI uptake may also contribute to the depletion ofnerve MI in diabetes (8) . MI depletion diminishes nerve phosphoinositide turnover (9) , interfering with (Na,K)-ATPase regulation (9) (10) (11) (12) (13) by a protein kinase-C-dependent mechanism (14) , thereby producing a four-to fivefold increase in intraaxonal sodium concentration (1, 3, 15, 16) , inactivation of nodal sodium channels, and a selective conduction block of large myelinated nerve fibers that acutely slows composite saltatory conduction (1, 3, 15, 16) . Increased intracellular sodium reduces the transmembrane gradient driving sodium-dependent MI uptake, further depleting MI and completing a self-reinforcing metabolic defect (8, 13) .
The role of this metabolic and biophysical cascade in the development ofthe subsequent morphological abnormalities that characterize human and murine diabetic neuropathy has not been satisfactorily explored (1, 2) . The initial characteristic morphometric abnormality in the peripheral neuropathy of the spontaneously diabetic Bio-breeding (BB) rat occurs within the first 3 wk of diabetes and consists of localized swelling of large myelinated nerve fibers in the region of the node of Ranvier (1, 3) . This swelling and the accompanying four-to fivefold increase in intraaxonal sodium are prevented by insulin replacement therapy that normalizes blood glucose and nerve conduction velocity (1, 3) . With more prolonged hyperglycemia, nodal swelling gives rise to axo-glial dysfunction (17) accompanied by apparent loss offunctional sodium channels from the node, neither ofwhich is acutely corrected by subsequent insulin replacement therapy despite rapid normalization of both MI content and (Na,K)-ATPase activity (13, 17) . Conceptually, the intracellular accumulation of either sorbitol (18) or sodium (3), through either aldose reductase activation or the MI-related (Na,K)-ATPase defect, respectively, could explain the early acute paranodal swelling thought to underlie axo-glial dysfunction.
Hence, the ability of insulin replacement, ARI administration and MI supplementation to reverse paranodal swelling was explored in the acutely diabetic BB rat, whose fidelity as a model for human disease is highlighted by the recent identification of paranodal swelling and axo-glial dysfunction in sural nerve biopsies from patients with diabetic neuropathy (19) . Insulin replacement, ARI administration, or MI supplementation completely reversed paranodal swelling as assessed by ratio of the paranodal fiber diameter to the internodal length. All three therapies correct MI depletion and (Na,K)-ATPase inactivation, whereas only insulin replacement and ARI treatment but not MI supplementation prevent sorbitol accumulation (6, 20) ; hence, paranodal swelling in diabetic nerve most likely reflects the intracellular accumulation of sodium due to decreased (Na,K)-ATPase activity rather than sorbitol accumulation. (17) . Upon detection of glucosuria and hyperglycemia, the newly diabetic rats were immediately begun on small daily doses (0.5-3.0 U * d-') of protamine zinc insulin (PZI), (Connaught Laboratories, Ltd., Toronto, Ontario), designed to maintain blood glucose levels between 350 and 450 mg* dl-' (17) . 3 wk thereafter, age-matched diabetic animals were randomly distributed into four experimental groups. "Baseline" diabetics were sacrificed immediately in orderto obtain baseline structural and morphometric parameters (3) . The other experimental groups were entered into a 3-wk study period during which: "insulin-deficient" diabetics were maintained hyperglycemic on small daily doses of PZI; "ARI-treated" diabetics were maintained insulin deficient on small doses of PZI but were given the ARI Statil (Stuart Pharmaceuticals, Wilmington, DE)25 mg* kg-' * d-' ina 10mg * ml-aqueous solution by gastric intubation; and "MI-treated" diabetics were maintained insulin deficient on small doses of PZI but in addition received MI, 670 mg kg-' d' in a 133-mg ml-' aqueous solution by gastric intubation (6) . These groups were compared to a similarly aged previously reported group of "insulin-replaced" diabetics treated aggressively with larger PZI doses (3.0-6.0 U d-') adjusted for changes in blood glucose in order to achieve and maintain euglycemia (3). End-point measurements (nerve conduction, morphological and biochemical assessments) were performed by investigators unaware of the identity of the examined material.
Electrophysiological studies. Animals were lightly anesthetized with ethyl ether (Fisher Scientific Company, Fair Lawn, NJ). Motor nerve conduction velocity (MNCV) was determined noninvasively in the sciaticposterior tibial conduction system in a temperature controlled environment as previously described in detail (21) . Briefly, the left sciatic-tibial nerve was stimulated proximally at the sciatic notch and distally at the ankle via bipolar electrodes using supramaximal stimuli (8 V) from a stimulater (TM 501, Tektronix, Inc., Beaverton, OR) at 20 Hz. Evoked muscle potential amplitudes (EMPA) were collected from the first interosseous space of the hindpaw by a unipolar platinum recording electrode and displayed on a Tektronix 511 storage oscilloscope. Motor nerve conduction velocity was calculated by subtracting the distal from the proximal latency measured in milliseconds from stimulus artifact to take off of the evoked muscle potential; the resultant difference was divided into the distance between the stimulating electrodes measured in millimeters, yielding a value for MNCV in meters per second. MNCV and EMPA were measured on a weekly basis throughout the study (21) .
Tissue collection. On the day after the final MNCV determination, nonfasted animals were anesthetized with Na pentobarbital (50 mg* kg). Mid-thigh segments of the left and right sciatic nerves were surgically removed, weighed, and processed either for enzymatic ATPase measurements or for gas-liquid chromatographic determination ofMI content as previously described in detail (11) . The right proximal sural nerve (opposite to the side on which MNCV was performed) was fixed in situ for 10 min by a cacodylate buffered (pH 7.40) 2.5% (vol/vol) glutaraldehyde fixative adjusted to an osmolality of 300 mosmol with sucrose (17) .
Biochemical measurements. Sciatic nerve MI was determined gasliquid chromatographically in protein-free Somogyi filtrates of sciatic nerve homogenates as previously described (1 1, 20) . Sciatic nerve (NaK)-ATPase activity was measured enzymatically as ouabain-inhibited ATPase activity in freshly prepared crude homogenates of whole sciatic nerve as previously described in detail (11) . Briefly, nerve segments were minced and homogenized at 4VC in 2 ml of0.2 M sucrose-0.02 M Tris-HCI pH 7.5. 5-20 ,g ofhomogenate was assayed spectrophotometrically in I ml of 100 mM NaCi, 10 mM KCa, 2.5 mM MgCI2, I mM Tris-ATP, I mM tri(cyclohexylammonium) phosphoenolpyruvate, 30 mM imidazole-HCI buffer (pH 7.3), 0.15 mM NADH, 50 ug of lactate dehydrogenase and 30 sg of pyruvate kinase (22) . ATPase activity in the presence of 0.10 mM ouabain was defined as the ouabain-uninhibitable ATPase fraction, since preliminary experiments had indicated that maximum ouabain inhibition is obtained at this concentration (11) . Ouabaininhibitable ATPase activity, a precise measurement of (Na,K)-ATPase activity in rat sciatic nerve, was defined as the arithmetic difference between composite and ouabain-uninhibitable ATPase activities (11) .
Teasedfiber analysis. The proximal portion of the sural nerve was post-fixed and stained in cacodylate-buffered 1% (vol/vol) osmium tetroxide, and 54±3 individual fibers were teased from each sural nerve segment in Epon (3). The teased fibers were examined under phase contrast illumination at a magnification of X 320 and internodal length measured (3). The corresponding paranodal fiber diameter was determined by measuring the maximum fiber width within a 30-Mm distance of both nodes of Ranvier bordering each internodal segment, and the mean value recorded for internode (3). The mean internodal length for each fiber was plotted on the ordinate, and the paranodal fiber diameter was plotted on the abscissa, and the slope of the linear regression was used to define the paranodal fiber diameter to internodal length ratio (3).
Statistics. Data are mean±SEM, significance ofdifference is calculated by Student's t test, and linear regessions are analyzed by the method of least squares.
Results
Clinical responses to insulin replacement, ARI, and MI therapy in BB diabetic rats (Table I) . At baseline, following 3 wk of insulin deficiency, body weight was reduced, blood glucose was elevated, and tibial MNCV and EMPA were reduced similarly in all five diabetic groups compared with nondiabetic BB controls (Table I) . Body weight, blood glucose, and tibial MNCV and EMPA remained abnormal for the additional 3-wk study period in insulin-deficient diabetics maintained on small doses of PZI (Table I) . 3 wk of intensive insulin therapy in insulin replaced diabetics normalized the rate of weight gain (Table I) (Table II) . Sciatic nerve MI content was significantly reduced in insulin-deficient diabetics compared with nondiabetic controls. As in the streptozotocin- (20) and chronically diabetic BB (3, 13) rat, intensive insulin therapy in the "insulin replaced" diabetics corrected the nerve MI depletion resulting from insulin deficiency (Table II) . Both ARI and MI treatment also corrected nerve MI depletion in the ART-treated and MI-treated BB diabetics as previously shown for the streptozotocin-induced diabetic rat (4) (5) (6) 20) .
(Na,K)-ATPase activity. Neither 6 wk ofsustained hyperglycemia in the insulin-deficient diabetics, nor 3 wk of unmodified insulin deficiency followed by 3 wk ofART or MI administration statistically significantly altered composite ATPase activity in crude homogenates of sciatic nerve although composite activity tended to be lowest in the insulin-deficient diabetics (data not shown). However, the ouabain-inhibitable component ofATPase activity was reduced -28% in the insulin-deficient diabetics compared with the nondiabetic controls (Table TI) . 3 wk of intensive insulin therapy corrected this abnormality in the insulin- Diabetes-prone BB rats were monitored daily for spontaneous development of diabetes following which they were begun on small daily doses of insulin designed to assure survival but maintain hyperglycemia in the range of 350 mg-dl-1. Age-matched non-diabetes-prone BB rats were used as nondiabetic controls. 3 wk after the appearance of hyperglycemia i.e., at baseline, the diabetic rats were randomly assigned to the experimental groups. The baseline diabetics were immediately sacrificed for baseline morphometric studies, while the remaining groups were entered into a 3-wk study period, during which the insulin-deficient diabetic rats were maintained hyperglycemic on small daily doses of insulin, the "insulinreplaced" diabetics were treated intensively with insulin to normalize blood glucose, and the "ARI-treated" and "MI-treated diabetics were main- At the completion of the 3-wk study period, nondiabetic controls and BB diabetic rats treated as described in Methods and in Table I were anesthetized. Mid-thigh segments of the sciatic nerves were surgically removed, and either deproteinized and processed for gas-liquid chromatographic determination of MI, or homogenized in sucrose containing buffer for determination of composite and non-ouabain-inhibitable ATPase activity, using the enzymatic adenine-nucleotide-linked kinetic spectrophotometric method of Yoda and Yoda (22) . Ouabain-inhibitable ATPase activity, a measure of (Na,K)-ATPase activity in rat nerve (7, 11, 13, 17) , was defined as the arithmetic difference between total and non-ouabain-inhibitable ATPase activity, and was expressed per mg wet wt of nerve. The differences between groups were not changed when the ATPase activities were expressed per mg Lowry protein (data not shown). Values for "insulin-replaced" diabetics are from a previously reported series (13) and are shown for comparison only.
replaced diabetics. Aldose reductase inhibitor and MI therapy in the hyperglycemic BB rats increased sciatic nerve ouabaininhibitable ATPase activity in the ARI-treated and MI-treated diabetics to 94 and 97%, respectively, ofthat in the nondiabetic control (Table II) . In contrast, residual ATPase activity in the presence of inhibiting concentrations of ouabain ("ouabain uninhibitable ATPase activity") was similar across experimental groups (except the insulin-replaced diabetics whose composite activity was identical to their contemporaneous nondiabetic controls [13] ). Thus, the effects of insulin deficiency and ARI or MI administration were primarily confined to the ouabaininhibitable (Na,K)-ATPase fraction, which in rat sciatic nerve is a reliable estimate of (Na,K)-ATPase activity (7, 11, 13, 17) . Qualitative assessment ofteasedfibers (Fig. 1) . Teased myelinated nerve fibers from baseline and insulin-deficient diabetics exhibited marked swelling at or near the node of Ranvier compared with teased fibers from nondiabetic controls (3) (Fig. 1 (Figs. 2 and 3) . Linear regression analysis of internodal length vs. paranodal fiber diameter confirmed the impression that paranodal fiber diameter was enlarged in untreated insulin deficiency diabetes. Internodal fiber length and paranodal fiber diameter were linearly related in all six experimental groups (nondiabetic controls, and baseline, insulin-deficient, insulin-replaced, ARI-treated and MI-treated diabetics, Figs. 2 and 3) . At baseline, the slope of the regression line was significantly shifted toward larger paranodal fiber diameters in the baseline diabetics compared with their age-matched nondiabetic controls (P < 0.001) (Fig. 2, a and b) .
At followup 3 wk later, the slope of the regression line was not significantly shifted in the older nondiabetic controls compared with the younger nondiabetic controls at baseline (compare a b Figure 1 . Effect of insulin deficiency, ARI treatment and MI supplementation on the appearance of the node of Ranvier of large myelinated fibers from the sural nerve of spontaneously diabetic BB rats. BB rats with spontaneous insulin deficiency of 3 wk duration were randomly distributed into experimental groups that remained insulin deficient without treatment, or were treated with an ARI or MI supplementation for an additional 3 wk. Photomicrographs of osmicated teased single fibers compare parano-C dal fiber appearance in (a) a nondiabetic control rat, (b) an insulin-deficient diabetic rat, (c) an ARI-treated diabetic rat, and (d) a MI-treated diabetic rat. Marked paranodal swelling that progressively tapered off toward the internodal areas was readily apparent in the untreated insulin-deficient dia-1 Juxtanodal fiber diameter (Aim) Figure 2 . Linear regression analysis of internodal length vs. paranodal fiber diameter in nondiabetic controls (a) and baseline diabetics (b) at the beginning of the 3-wk study period. The analysis showed a significant shift of the slope of the regression line toward larger paranodal fiber diameters in the baseline diabetics (b) confirming the impression, illustrated in Fig. 1 , that insulin deficiency is assaciated with paranodal swelling.
Figs. 2 and 3 a). The slope of the regression line was significantly shifted toward larger fiber diameters in insulin-deficient diabetics compared with their age-matched nondiabetic controls at followup (P < 0.001) (Fig. 3, a and b) . Intensive insulin therapy, or administration of an ARI or MI significantly increased the slope of the regression lines in the insulin-replaced, ARI-treated and MI-treated diabetics (Fig. 3 , c-e) (all P < 0.001 vs. both baseline and insulin-deficient diabetics) rendering them statistically indistinguishable from that of the baseline and followup nondiabetic controls. These alterations in the ratio of internodal length to paranodal fiber diameter could not be explained on the basis of shortened internodes in the baseline or insulin-deficient diabetics, since the ratio of internodal length to internodal fiber diameter was the same, and the mean internodal lengths were unaltered among the six experimental groups (data not shown). These data are consistent with the conclusion that paranodal fiber diameter was increased in the baseline and Presumably paranodal swelling would be prevented by therapy that blocks the initial depletion of MI and reduction in (Na,K)-ATPase activity (4-7, 1 1), and the resultant rise in intracellular sodium shortly after the onset of diabetes (3) . Ultrastructural and electrophysiological studies equating paranodal swelling with sodium accumulation (3, 15) and distention (3, 19) in the axon rather than the Schwann cell, combined with the identification of (Na,K)-ATPase (25) but not aldose reductase (24, 29) in the axon, further implicate the MI-related (Na,K)-ATPase defect rather than sorbitol accumulation in the swelling of large myelinated nerve fibers in the BB rat. On the other hand, the largely unanticipated but often confirmed observation that inhibitors ofthe enzyme aldose reductase, located primarily in the Schwann cell, prevent the axonal (1, 3, 15) MI-related (Na,K)-ATPase defect (4-7, 1 1), implies the existence of unexplored but physiologically important interactions between the axon and Schwann cells at the node of Ranvier.
Paranodal swelling abates with the appearance of axo-glial dysjunction in the BB rat (3, 17) , presumably reflecting the diminished demand on (NaK)-ATPase-dependent sodium extrusion following nerve depolarization conferred by the associated decrease in nodal voltage-dependent sodium permeability (3, 15) . Paranodal swelling and axo-glial dysjunction correlate closely in sural nerve biopsies from patients with chronic neuropathy complicating insulin-dependent diabetes mellitus (IDDM), and are both related to duration and severity of hyperglycemia (19) . Mechanical stresses associated with paranodal swelling presumably contribute to the disruption ofjunctional complexes between the axolemma and terminal loops of myelin, resulting in axo-glial dysjunction (17) . Hence, for the first time, a defined cause and effect chain of metabolic, biophysical, and ultrastructural abnormalities has emerged linking insulin deficiency and hyperglycemia, on one hand, with characteristic structural abnormalities in human and murine diabetic neuropathy on the other, i.e., paranodal swelling and axo-glial dysjunction. These structural lesions account for poorly reversible nerve conduction slowing in diabetic rats (I13, 17) , and are viewed Paranodal Swelling in the Spontaneously Diabetic Bio-breeding Rat 1483 Juxtanodal diameter (Cm) Figure 3 . Linear regression analysis of internodal length vs. paranodal fiber diameter in the nondiabetic controls and 4 diabetic experimental groups at the conclusion of the 3 wk study period. (a) Nondiabetic controls, (b) insulin-deficient diabetics, (c) insulin-replaced diabetics, (d) ARI-treated diabetics, and (e) MI-treated diabetics. 6 wk of insulin deficiency significantly shifted the slope of the regression line towards as a precursor to paranodal demyelination and probably nerve fiber loss in patients with diabetic neuropathy (19 
